Thanks to the specific technology developed by ERYtech Pharma, a powerful platform has been validated:

• to develop new products with long circulating action with no release of the compounds:
  - Bio-reaction into the red cells (Graspa®)
  - Oxygen-hemoglobin affinity reduction (Grara) 

• to rapidly target specific cells involved in the erythrophagocytosis (Kupffer cells, dendritic cells, macrophages): Immune Modulation Platform
  - Immuno-Inflammation (Gr-Rnai)
  - Immune Tolerance Induction (Gr-Tol)
  - Immuno Stimulation (Gr-Vax).